NewcelX Stock Moves Up Ahead of FDA Meeting on Diabetes Treatment
NewcelX Ltd. shares edged up 0.6% to $3.18 in midday Nasdaq trading Thursday as investors awaited a late-June FDA meeting on its stem cell therapy for type 1 diabetes. The company submitted pre-IND materials for NCEL-101 and ended 2025 with $2.2 million in cash after an $8.3 million net loss.